Home » Technology » Cognivia expands its portfolio of predictive solutions by introducing Compl-AI©™

Cognivia expands its portfolio of predictive solutions by introducing Compl-AI©™

Last News

(Information sent by the signed company)

-Cognivia expands its portfolio of predictive solutions by introducing Compl-AI©™, an innovative solution that predicts the risk of patient non-compliance and abandonment.

It has been shown that Compl-AI©™predicts non-adherence to treatment and the risk of abandonment. With the use of Compl-AI, the patient recruitment and engagement strategy can be optimized to improve patient outcomes. Learn more about Compl-AI in the Xtalks webinar on June 21.

MONT-SAINT-GUIBERT, Belgium, May 24, 2023/PRNewswire/ — Cogniviaa clinical trial technology company that combines machine learning with sophisticated assessment of patient characteristics and characteristics proud to announce the launch of its latest innovation: Compl-AI©™.

Compl-AI is a predictive tool that helps clinical trial sponsors optimize patient recruitment and engagement strategies. Lack of compliance in clinical trials and high dropout rates make determining efficacy and safety more difficult. Compl-AI addresses this common challenge by qualifying patient behavior on screening using machine learning. The Compl-AI Patient Behavior Score allows for individual patient engagement strategies. Beyond clinical research, Compl-AI offers healthcare providers a unique approach to personalize and optimize their patient support for better treatment adherence.

“Cognivia is committed to cracking the code of the complex relationship between patient characteristics and behavior,” said the CEO Dominique Demolle, PhD. “Individual patient characteristics and experiences have a significant impact on clinical trial data. With Compl-AI, we are excited about the possibility to personalize patient engagement strategies and continue to drive drug development into a new frontier.” “.

With Compl-AI, sponsors can detect the risk of non-adherence and dropout prior to initiation and monitor it throughout their clinical trial. To learn more about how Compl-AI works and the benefits of this innovative approach, contact the CEO Dominique DemollePhD, and COO Chantal Gossuin for the Xtalks webinar on June 21:

Patient Compliance and Engagement: Predicting the Risks of Nonadherence and Dropout

  • Wednesday, June 21, 2023
  • 10am EDT (N/A)/ 3pm BST (United Kingdom) / 4pm CEST (EU-Central)

Register for the webinar hereand learn more about Compl-AI here.

About Cognivia

Cognivia is the first and only company to combine the quantification of patient psychology with artificial intelligence (AI)/machine learning (ML) to improve the measurement of therapeutic efficacy in clinical trials and beyond. Cognivia’s technologies predict patient behavior and treatment response in clinical trials using ML-powered predictive algorithms based on a quantitative understanding of patients’ psychological characteristics, expectations and beliefs collected through proprietary and specific questionnaires developed for that goal. Cognivia aims to harness the “power of the mind” and quantify this unique phenomenon to improve clinical trial success rates, de-risk drug development, and ultimately improve healthcare.


Alex Hernandezalex@altitudemarketing.com610-421-8601 ext. 104

Logo – https://mma.prnewswire.com/media/2082754/Cognivia_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/cognivia-extends-its-portfolio-of-predictive-solutions-presenting-compl-ai-301833544.html

Scroll to Top